PCM
SCMP

Prelude Capital Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Prelude Capital Management’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-674,446
Closed -$12.1M – 1887
2017
Q4 		$12.1M Buy
674,446
+668,146
+10,605% +$8.23M 0.97% 15
2017
Q3 		$74K Hold
6,300
– – 0.01% 986
2017
Q2 		$66K Sell
6,300
-24,749
-80% -$252K 0.01% 910
2017
Q1 		$342K Buy
31,049
+19,649
+172% +$228K 0.03% 397
2016
Q4 		$154K Sell
11,400
-3,800
-25% -$53K 0.02% 676
2016
Q3 		$187K Buy
15,200
+3,239
+27% +$38.2K 0.02% 588
2016
Q2 		$131K Buy
11,961
+9,841
+464% +$110K 0.02% 650
2016
Q1 		$23K Sell
2,120
-8,980
-81% -$113K ﹤0.01% 1099
2015
Q4 		$192K Buy
11,100
+3,490
+46% +$62.6K 0.03% 590
2015
Q3 		$151K Sell
7,610
-14,490
-66% -$332K 0.02% 706
2015
Q2 		$363K Sell
22,100
-600
-3% -$10.4K 0.05% 391
2015
Q1 		$353K Buy
22,700
+3,900
+21% +$60.5K 0.05% 449
2014
Q4 		$268K Sell
18,800
-8,800
-32% -$92.9K 0.04% 537
2014
Q3 		$179K Sell
27,600
-8,300
-23% -$55.1K 0.03% 759
2014
Q2 		$248K Buy
35,900
+33,100
+1,182% +$234K 0.03% 660
2014
Q1 		$20K Sell
2,800
-7,068
-72% -$60.5K ﹤0.01% 1694
2013
Q4 		$93K Buy
+9,868
New +$70.4K 0.02% 866

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Prelude Capital Management's SCMP Position: Q1 2018 in Review

Prelude Capital Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 674,446 shares — an estimated $12.1M sold.

Prelude Capital Management first reported a position in SCMP in Q4 2013 and held it in 17 quarters. The position peaked at $12.1M in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Prelude Capital Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Prelude Capital Management sold 674,446 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $12.1M.
  • Prelude Capital Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2013 and held it in 17 quarters.
  • Prelude Capital Management's Sucampo Pharmaceuticals, Inc. position peaked at $12.1M in Q4 2017.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Prelude Capital Management's 13F filing for Q1 2018, filed 15 May 2018.